Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Alpine Immune Sciences, Inc.

R&D Spending: Teva vs. Alpine - A Decade of Innovation

__timestampAlpine Immune Sciences, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014121995471488000000
Thursday, January 1, 2015160540001525000000
Friday, January 1, 2016233160002111000000
Sunday, January 1, 2017106260001848000000
Monday, January 1, 2018289700001213000000
Tuesday, January 1, 2019358470001010000000
Wednesday, January 1, 202027185000997000000
Friday, January 1, 202158742000967000000
Saturday, January 1, 202270243000838000000
Sunday, January 1, 202380904000953000000
Monday, January 1, 2024998000000
Loading chart...

Unleashing insights

Innovation in Pharmaceuticals: A Comparative Analysis

In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Teva Pharmaceutical Industries Limited and Alpine Immune Sciences, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Teva's R&D expenses have shown a downward trend, decreasing by approximately 36%, from $1.49 billion to $953 million. In contrast, Alpine Immune Sciences has steadily increased its R&D spending by over 560%, from $12 million to $81 million. This stark difference highlights Alpine's aggressive push towards innovation, despite its smaller scale compared to Teva. As the pharmaceutical industry continues to face challenges and opportunities, these spending patterns offer insights into each company's strategic priorities and potential future breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025